Loading...
Last update:  May 26, 2023
08:28 +1GMT

Allergenic Molecule  Act d 2Homo sapiens  
Epidemiology from Literature
CohortYearCountryTestSubjectsPositive (%)Bibliography
1.5 - Atopic Dermatitis, Diagnosed2014NetherlandsIgE21111.80020140331, Rockmann H
3.2.1 - Source Sensitized (IgE)2013ItalyIgE28420.07020130420, Palazzo P
1.5 - Atopic Dermatitis, Diagnosed2013GermanyIgE1402.14020130111, Ott H
1.3 - Rhinitis, Diagnosed2013BrazilIgE1010.00020130912, Lacerda Araujo LM
1.11 - Esophagitis, Diagnosed2013NetherlandsIgE763.90020131020, van Rhijn BD
5.2.1 - Source Exposed (Symptoms, SPT)2013ItalyIgE494.08020130420, Palazzo P
5.2.1 - Source Exposed (Symptoms, SPT)2013ItalyIgE (IB)4961.22020130420, Palazzo P
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2013ItalyIgE365.55020130420, Palazzo P
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2013ItalySPT3613.88020130420, Palazzo P
1.11 - Esophagitis, Diagnosed2013SwitzerlandIgE3511.43020130605, Simon D
6.2 - General Population (Adults)2012SwedenIgE3710.00020120528, Patelis A
1.8 - Fruit Allergy2012SpainIgE2128.00020120912, Palacin A
5.1.1 - Source Exposed (Symptoms)2012France / Italy / Netherlands / Switzerland / United KingdomIgE18112.00020121112, Le TM
1.9 - Pollen Allergy2012SpainIgE1176.00020120912, Palacin A
5.3.1 - Source Exposed (Symptoms, IgE)2012BelgiumIgE999.09020110223, De Knop KJ
1.2.1 - Asthma, Diagnosed (Adults)2012SwedenIgE960.00020120528, Patelis A
5.1.1 - Source Exposed (Symptoms)2012Bulgaria / Czech Republic / Lithuania / PolandIgE562.00020121112, Le TM
5.1.1 - Source Exposed (Symptoms)2012Greece / SpainIgE4511.00020121112, Le TM
5.1.1 - Source Exposed (Symptoms)2012IcelandIgE294.00020121112, Le TM
10.1 - Normal Control2012BelgiumIgE270.00020110223, De Knop KJ
3.2.1 - Source Sensitized (IgE)2011ItalyIgE83559.04020110211, DAvino R
4.1.6 - Heterologous Source Sensitized (High IgE)2011ItalyIgE21441.12020110211, DAvino R
4.1.2 - Heterologous Source Sensitized (Symptoms, SPT)2011ChinaIgE1000.00020111214, Zheng YW
4.1.6 - Heterologous Source Sensitized (High IgE)2011AustriaIgE601.66020110211, DAvino R
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2010ItalyIgE2378.02020101118, Bublin M
3.1.4 - Source Sensitized (SPT, IgE)2010Italy / Austria / Switzerland / NetherlandsIgE1980.51020101118, Bublin M
4.1.2 - Heterologous Source Sensitized (Symptoms, SPT)2010SpainIgE3158.06020100812, Palacin A
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2010SwitzerlandIgE3010.00020100111, Bublin M
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2009BelgiumIgE372.70020090826, Ebo DG
10.1 - Normal Control2009BelgiumIgE260.00020091121, Ebo DG
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2009BelgiumIgE220.00020091121, Ebo DG
4.1.5 - Heterologous Source Sensitized (IgE)2009BelgiumIgE2020.00020091121, Ebo DG
1.5 - Atopic Dermatitis, Diagnosed2009GermanyIgE2020.00020091005, Ott H
5.2.1 - Source Exposed (Symptoms, SPT)2008SpainIgE9264.13020080119, Palacin A
5.2.1 - Source Exposed (Symptoms, SPT)2008SpainSPT2552.00020080119, Palacin A
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2002YugoslaviaIgE580.0002002, Gavrovic-Jankulovic M
Developed by
Panservice